Genetic alterations of K‐ras may reflect prognosis in stage III colon cancer patients below 60 years of age

Genetic alterations that are closely associated with patient prognosis can be landmarks of definitive therapeutic targets as well as useful biomarkers in human cancer clinics.

[1]  L. Terracciano,et al.  Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosis , 2010, International journal of cancer.

[2]  T. Winder,et al.  Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. , 2009, Oncology reports.

[3]  M. Somerfield,et al.  American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Siannis,et al.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. , 2008, The Lancet. Oncology.

[5]  I. Okayasu,et al.  Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer. , 2007, International journal of radiation oncology, biology, physics.

[6]  W. Bernardo,et al.  DNA Ploidy Status and Prognosis in Colorectal Cancer: A Meta-Analysis of Published Data , 2007, Diseases of the colon and rectum.

[7]  Takatoshi Nakamura,et al.  Irinotecan and S-1 neoadjuvant chemoradiation therapy in patients with advanced rectal cancer. , 2007, Hepato-Gastroenterology.

[8]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[9]  N. Petrelli,et al.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Manuel Hidalgo,et al.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Silvia Benvenuti,et al.  Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.

[12]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[14]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[15]  R. Wolff,et al.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.

[16]  Shiu-Ru Lin,et al.  APC, K-ras, and p53 Gene Mutations in Colorectal Cancer Patients: Correlation to Clinicopathologic Features and Postoperative Surveillance , 2005, The American surgeon.

[17]  K. Kinzler,et al.  Somatic mutations of EGFR in colorectal cancers and glioblastomas. , 2004, The New England journal of medicine.

[18]  Gong Chen,et al.  Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer. , 2004, World journal of gastroenterology.

[19]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[20]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[21]  Daniel Jones.  Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.

[22]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[23]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[25]  J. Fletcher,et al.  Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[27]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[28]  S. Goodman,et al.  Counting alleles to predict recurrence of early-stage colorectal cancers , 2002, The Lancet.

[29]  B. Leggett,et al.  Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. , 2001, The American journal of pathology.

[30]  이석호,et al.  Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.

[31]  I. Okayasu,et al.  Novel method for simultaneous analysis of p53 and K-ras mutations and p53 protein expression in single histologic sections. , 2001, Archives of pathology & laboratory medicine.

[32]  B. Leggett,et al.  Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. , 2001, Cancer research.

[33]  J. Herman,et al.  K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Sándor,et al.  The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. , 2000, Anticancer research.

[35]  F. Bosman,et al.  p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. , 2000, European journal of cancer.

[36]  H. Yokozaki,et al.  Molecular–pathological diagnosis of gastrointestinal tissues and its contribution to cancer histopathology , 1999, Pathology international.

[37]  S. Hirota,et al.  Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. , 1999, Cancer research.

[38]  D. Schaid,et al.  Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. , 1999, Journal of the National Cancer Institute.

[39]  G. Capellá,et al.  p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  I. Okayasu,et al.  k‐ras Point Mutations in the Supernatants of Pancreatic Juice and Bile Are Reliable for Diagnosis of Pancreas and Biliary Tract Carcinomas Complementary to Cytologic Examination , 1999, Japanese journal of cancer research : Gann.

[41]  I. Okayasu,et al.  Detection of K-ras point mutations in the supernatants of peritoneal and pleural effusions for diagnosis complementary to cytologic examination. , 1998, American journal of clinical pathology.

[42]  A. Norman,et al.  Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. , 1998, Journal of the National Cancer Institute.

[43]  D. Roder,et al.  Somatic mutations, acetylator status, and prognosis in colorectal cancer , 1998, Gut.

[44]  R. Kerbel,et al.  Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Benhattar,et al.  The type of K-ras mutation determines prognosis in colorectal cancer. , 1998, American journal of surgery.

[46]  K. Kinzler,et al.  Genetic instability in colorectal cancers , 1997, Nature.

[47]  G. Gaudernack,et al.  K-ras mutations and prognosis in large-bowel carcinomas. , 1997, Scandinavian journal of gastroenterology.

[48]  I. Okayasu,et al.  Simplified rapid non‐radioactive PCR‐SSCP method applied to K‐ras mutation analysis , 1996, Pathology international.

[49]  J. Arends,et al.  A detailed analysis of K‐ras point mutations in relation to tumor progression and survival in colorectal cancer patients , 1996, International journal of cancer.

[50]  B. Vogelstein,et al.  Genetic instability occurs in the majority of young patients with colorectal cancer , 1995, Nature Medicine.

[51]  K. Omura,et al.  Prognostic factors of colorectal cancer: K‐ras mutation, overexpression of the p53 protein, and cell proliferative activity , 1994, Journal of surgical oncology.

[52]  S. Shirasawa,et al.  Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. , 1993, Science.

[53]  J. Benhattar,et al.  Prognostic significance of K-ras mutations in colorectal carcinoma. , 1993, Gastroenterology.

[54]  R. Fourney,et al.  Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. , 1991, Cancer research.

[55]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[56]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[57]  C. Compton,et al.  The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. , 2007, Gastroenterology.